KALV
NASDAQ · Biotechnology
Kalvista Pharmaceuticals Inc
$26.73
+0.01 (+0.04%)
Open$26.74
Previous Close$26.72
Day High$26.75
Day Low$26.70
52W High$26.85
52W Low$9.83
Volume—
Avg Volume11.03M
Market Cap1.37B
P/E Ratio—
EPS$-1.15
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+142.3% upside
Current
$26.73
$26.73
Target
$64.76
$64.76
$35.35
$64.76 avg
$75.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 46.75M | 272.43M | 275.70M |
| Net Income | -104,325,934 | -77,974,346 | -85,417,882 |
| Profit Margin | -223.2% | -28.6% | -31.0% |
| EBITDA | -102,047,605 | -125,574,606 | -125,457,307 |
| Free Cash Flow | — | -59,177,907 | -68,220,346 |
| Rev Growth | — | +3.3% | +15.2% |
| Debt/Equity | 1.11 | 0.07 | 0.09 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |